Navigation Links
DSM and Codexis Sign Enzyme Supply Agreement
Date:2/16/2011

PARSIPPANY, N.J. and REDWOOD CITY, Calif., Jan. 12, 2011 /PRNewswire/ -- The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn™ route scouting services.

Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste.  Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.

The DSM InnoSyn™ route scouting team provides value creating solutions to its customer by integrating cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.

"Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners," said Joseph Sarret, M.D., President, Codexis Pharmaceutical Services & Enzyme Products. "We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale."

Oliver May, Ph.D., Corporate Scientist and Business Manager for DSM's InnoSyn™ route scouting services commented: "One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM's capabilities to identify, develop and implement efficient enzymatic routes."

InnoSyn™ is a trademark of DSM

Codexis Codexis (Nasdaq: CDXS) is a clean technology company that develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with many leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals. More information: www.codexis.com

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information:  www.dsmpharmaceuticalproducts.com

DSM – the Life Sciences and Materials Sciences Company Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about Euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

Codexis Forward-Looking StatementsThis press release contains forward-looking statements relating to Codexis development of biocatalysts for use at DSM Pharmaceutical Products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis Quarterly Report on Form 10-Q dated November 4, 2010 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

DSM Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.For more information:DSMCodexisOliver May, Ph.D.

Media: Lyn ChristensonBusiness Manager, InnoSyn™

tel. +1 650 421 8144 tel. +31 (46) 4760551

lyn.christenson@codexis.com oroliver.may@dsm.com

Saskia Sidenfadentel. +1 212 827 3771ssidenfaden@mww.com   Investors: Robert Lawson tel. 650 421 8137robert.lawson@codexis.com
'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. DSM and Codexis Sign Enzyme Supply Agreement
2. 1 group of enzymes could have a positive impact on health, from cholesterol to osteoporosis
3. Team looks to the cow rumen for better biofuels enzymes
4. 2 bacterial enzymes confer resistanceto common herbicide, say MU researchers
5. How the hat fits: Structural biology study reveals shape of epigenetic enzyme complex
6. Chemists document workings of key staph enzyme -- and how to block it
7. Enzyme Engineering XXI
8. Scientists discover that a specific enzyme inhibitor may help control lung inflammation
9. UGA researchers identify key enzyme that regulates the early growth of breast cancer cells
10. Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
11. Gene variations that alter key enzyme linked to prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), Product ... by MarketsandMarkets, the market is expected to be worth USD 18.98 billion by ... Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... April 27, 2017 , ... This month Quorum ... solution that simplifies research studies, accelerates study startup, and improves participant engagement. Developed ... is the first and only IRB-integrated eConsent solution . , “Our mission ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin D can enhance ... ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... name change to Fluence Analytics. , Fluence Analytics provides proprietary hardware ... biopharmaceutical manufacturing processes and R&D applications. The company’s patented technologies improve production ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... the 2017 Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator ... forms of media to advocate for science, as he explains how innovation and ...
Breaking Biology Technology: